{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":24,"n_cols":5,"rows_kept":24,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[4,2,4,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[10,2,10,3],[13,2,13,3],[14,2,14,3],[18,2,18,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910461096003321"]
[null,null,"Titolo",null,"Antimicrobial chemotherapy / / Professor Peter Davey [and three others]"]
[null,null,"Pubbl/distr/stampa",null,"Oxford, [England] : , : Oxford University Press, , 2015"]
[{"$nulls":4},"©2015"]
[null,null,"ISBN",null,"0-19-100401-4"]
[{"$nulls":4},"0-19-176941-X"]
[{"$nulls":4},"0-19-100400-6"]
[null,null,"Edizione",null,"[Seventh edition.]"]
[null,null,"Descrizione fisica",null,"1 online resource (431 p.)"]
[null,null,"Disciplina",null,"616.90461"]
[null,null,"Soggetti",null,"Anti-infective agents"]
[{"$nulls":4},"Communicable diseases - Chemotherapy"]
[{"$nulls":4},"Electronic books."]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references at the end of each chapters and index."]
[null,null,"Nota di contenuto",null,"Cover; Preface; Contents; List of Abbreviations; Part 1 General properties of antimicrobial agents; 1 Mechanisms of action and resistance to modern antibacterials, with a history of their development; 2 Inhibitors of bacterial cell wall synthesis; 3 Inhibitors of bacterial protein synthesis; 4 Synthetic antibacterial agents and miscellaneous antibiotics; 5 Antiviral agents; 6 Antiretroviral agents; 7 Drugs used in the treatment of viral hepatitis; 8 Antifungal agents; 9 Antiprotozoal and anthelminthic agents; Part 2 Resistance to antimicrobial agents; 10 The problem of resistance"]
[{"$nulls":4},"11 The genetics and mechanisms of acquired resistancePart 3 General principles of usage of antimicrobial agents; 12 Laboratory investigations and the treatment of infection; 13 General principles of the treatment of infection; 14 Pharmacokinetic and pharmacodynamic principles; 15 Prescribing in special groups: effects of age, pregnancy, body weight, and hepatic and renal impairment; 16 OPAT: outpatient parenteral antimicrobial therapy; 17 Adverse drug reactions, and patient safety; 18 Chemoprophylaxis and immunization; 19 Guidelines, formularies, and antimicrobial policies"]
[{"$nulls":4},"20 Antimicrobial stewardship, surveillance of antimicrobial consumption, and its consequencesPart 4 Therapeutic use of "]
[{"$nulls":4},"antimicrobial agents; 21 Respiratory tract infections; 22 Topical use of antimicrobial agents; 23 Urinary tract infections; 24 Sexually transmitted infections; 25 Gastrointestinal infections; 26 Serious bacterial bloodstream infections; 27 Bone and joint infections; 28 Infections of the central nervous system; 29 Skin and soft-tissue infections; 30 Tuberculosis and other mycobacterial diseases; 31 Infections in immunocompromised patients, including HIV/AIDS"]
[{"$nulls":4},"32 Viral infections33 Management of HIV infection; 34 Treatment of chronic viral hepatitis; 35 Parasitic disease; 36 The development and marketing of antimicrobial drugs; Appendix: Recommendations for Further Reading; Index"]
[null,null,null,"Sommario/riassunto","Antimicrobial agents are essential for the treatment of life-threatening infections and for managing the burden of minor infections in the community. In addition, they play a key role in organ and bone marrow transplantation, cancer chemotherapy, artificial joint and heart valve surgery. Unlike other classes of medicines, they are vulnerable to resistance from mutations in target microorganisms, and their adverse effects may extend to other patients (increased riskof cross-infection). As a consequence, there is a constant requirement for new agents, as well as practices that ensure the continu"]